New drug for kidney transplant recipients effective in humans

Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class co-stimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide similar patient and graft survival to cyclosporine but with fewer side effects and superior kidney function after 12 months.

Read the whole article on Science Daily

More from Science Daily